NASDAQ: FDMT
4d Molecular Therapeutics Inc Stock Ownership - Who owns 4d Molecular Therapeutics?

Insider buying vs selling

Have 4d Molecular Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Scott BizilyChief Legal Officer2025-10-241,084$6.49
$7.04kBuy
Scott BizilyChief Legal Officer2025-10-242,678$12.00
$32.14kSell
Scott BizilyChief Legal Officer2025-10-161,635$4.14
$6.77kBuy
Scott BizilyChief Legal Officer2025-10-161,635$10.17
$16.63kSell
Scott BizilyChief Legal Officer2025-10-092,408$10.00
$24.08kSell
Scott BizilyChief Legal Officer2025-09-232,407$8.00
$19.26kSell

1 of 1

FDMT insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when FDMT insiders and whales buy or sell their stock.

FDMT Shareholders

What type of owners hold 4d Molecular Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Bvf Inc8.10%4,629,289$49.95MInstitution
Ra Capital Management LP7.99%4,563,211$49.24MInstitution
Ra Capital Management LP7.99%4,563,211$49.24MInsider
Viking Global Investors LP7.43%4,247,914$45.83MInsider
Goldman Sachs Group Inc7.23%4,128,416$44.55MInstitution
Blackrock Inc6.77%3,869,130$41.75MInstitution
Vanguard Group Inc4.51%2,575,122$27.79MInstitution
Novo Holdings A3.50%2,000,000$21.58MInstitution
Janus Henderson Group PLC3.07%1,753,367$18.92MInstitution
David Kirn2.90%1,659,153$17.90MInsider

1 of 3

FDMT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
FDMT67.15%22.21%Net SellingNet Selling
MGTX56.34%43.66%Net SellingNet Selling
VSTM53.37%46.63%Net SellingNet Selling
OMER46.29%5.09%
CTMX80.23%12.77%Net SellingNet Selling

4d Molecular Therapeutics Stock Ownership FAQ

Who owns 4d Molecular Therapeutics?

4d Molecular Therapeutics (NASDAQ: FDMT) is owned by 67.15% institutional shareholders, 22.21% 4d Molecular Therapeutics insiders, and 10.64% retail investors. Ra Capital Management LP is the largest individual 4d Molecular Therapeutics shareholder, owning 4.56M shares representing 7.99% of the company. Ra Capital Management LP's 4d Molecular Therapeutics shares are currently valued at $49.97M.

If you're new to stock investing, here's how to buy 4d Molecular Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.